Abstract
BackgroundMesenchymal stem cells (MSCs) have important research value and broad application prospects in the cardiovascular disease. This study provides information on the latest progress, evolutionary path, frontier research hotspots, and future research developmental trends in this field.MethodsA knowledge map was generated by CiteSpace and VOSviewer analysis software based on data obtained from the literature on MSCs in the cardiovascular field.ResultsThe USA and China ranked at the top in terms of the percentage of articles, accounting for 34.306% and 28.550%, respectively. The institution with the highest number of research publications in this field was the University of Miami, followed by the Chinese Academy of Medical Sciences and Harvard University. The research institution with the highest ACI value was Harvard University, followed by the Mayo Clinic and the University of Cincinnati.The top three subjects in terms of the number of published articles were cell biology, cardiovascular system cardiology, and research experimental medicine. The journal with the most publications in this field was Circulation Research, followed by Scientific Reports and Biomaterials. The direction of research on MSCs in the cardiovascular system was divided into four parts: (1) tissue engineering, scaffolds, and extracellular matrix research; (2) cell transplantation, differentiation, proliferation, and signal transduction pathway research; (3) assessment of the efficacy of stem cells from different sources and administration methods in the treatment of acute myocardial infarction, myocardial hypertrophy, and heart failure; and (4) exosomes and extracellular vesicles research. Tissue research is the hotspot and frontier in this field.ConclusionMSC research has presented a gradual upward trend in the cardiovascular field. Multidisciplinary intersection is a characteristic of this field. Engineering and materials disciplines are particularly valued and have received attention from researchers. The progress in multidisciplinary research will provide motivation and technical support for the development of this field.
Highlights
Mesenchymal stem cells (MSCs) are widely perceived as a class of adult pluripotent stem cells with multiple differentiation potentials, which derived from mesoderm and neuroectoderm and do not express hematopoieticrelated markers [1]
The important biological characteristics of MSCs include its low level of expression of human leukocyte antigen class I molecules and CD40, CD40 ligand, CD80, or CD86, which is required to induce effector T cells [2]
Bonnet found that BMSCs induced in vitro can express platelet-derived growth factor receptor (PDGFR), smooth muscle myosin heavy chain 11 (SMMHC11), and myoglobulin light chain 2 (MLC2), which is similar to that observed in aortic smooth muscle cells, and BMSCs have similar electrophysiological activity and contraction ability [4]
Summary
Mesenchymal stem cells (MSCs) are widely perceived as a class of adult pluripotent stem cells with multiple differentiation potentials, which derived from mesoderm and neuroectoderm and do not express hematopoieticrelated markers [1]. The important biological characteristics of MSCs include its low level of expression of human leukocyte antigen class I molecules and CD40, CD40 ligand, CD80, or CD86, which is required to induce effector T cells [2]. MSCs have low immunogenicity and immunoregulatory effects, which can affect every cell of the immune system through cell-cell interactions and paracrine effects [3]. Based on these special biological characteristics, MSCs have important research value and broad application prospects. MSCs induce the differentiation of cardiomyocytes and vascular endothelial cells. Mesenchymal stem cells (MSCs) have important research value and broad application prospects in the cardiovascular disease. This study provides information on the latest progress, evolutionary path, frontier research hotspots, and future research developmental trends in this field
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
